Article

Daily Niacin Vitamins Help Cut Skin Cancer Risk

Author(s):

Twice-daily niacin pill for 12-months reduced the incidence of new non-melanoma skin cancers.

Twice-daily niacin pill for 12-months reduced the incidence of new non-melanoma skin cancers.

There’s more to skincare and melanoma prevention than lathering on the SPF or staying out of the sun.

Taking niacin vitamins (nicotinamide or vitamin B3) daily would tremendously help people lower their recurrent risk for skin cancer, according to a study recently published in The New England Journal of Medicine.

The protective characteristics of B3 aren’t anything new — previous research has supported this claim.

However, researchers from Australia recently studied 386 patients who had already been diagnosed with non-melanoma skin cancers at least twice, as their prior diagnosis with squamous cell carcinomas classified them as high risk for repeated cancerous spots.

The study results indicated that administered as a twice-daily pill for a 12-month term, niacin vitamins did reduce the incidence of new non-melanoma skin cancers by 23% compared with placebo. The vitamins also decreased the incidence of pre-cancerous sunspots by approximately 15%.

Delphine Lee, MD, PhD, dermatologist and director of translational immunology, John Wayne Cancer Institute, Santa Monica, CA, remarked, “This is such a simple solution and this study should change what all doctors do when it comes to preventing skin cancer in high-risk patients.”

Diona Damian, MD, professor of dermatology, University of Sydney and Royal Prince Alfred Hospital, concluded in a news release. “This is the first clear evidence that we can reduce skin cancers using a simple vitamin, together with sensible sun protection. We hope that these findings can be immediately translated into clinical practice. However, people at high risk of skin cancer still need to practice safe behavior, use sunscreens, and have regular check-ups with their doctors.”

Related Videos
Anthony Perissinotti, PharmD, BCOP, discusses unmet needs and trends in managing chronic lymphocytic leukemia (CLL), with an emphasis on the pivotal role pharmacists play in supporting medication adherence and treatment decisions.
Image Credit: © alenamozhjer - stock.adobe.com
pharmacogenetics testing, adverse drug events, personalized medicine, FDA collaboration, USP partnership, health equity, clinical decision support, laboratory challenges, study design, education, precision medicine, stakeholder perspectives, public comment, Texas Medical Center, DNA double helix
pharmacogenetics challenges, inter-organizational collaboration, dpyd genotype, NCCN guidelines, meta census platform, evidence submission, consensus statements, clinical implementation, pharmacotherapy improvement, collaborative research, pharmacist role, pharmacokinetics focus, clinical topics, genotype-guided therapy, critical thought
Image Credit: © Andrey Popov - stock.adobe.com
Image Credit: © peopleimages.com - stock.adobe.com
TRUST-I and TRUST-II Trials Show Promising Results for Taletrectinib in ROS1+ NSCLC
World Standards Week 2024: US Pharmacopeia’s Achievements and Future Focus in Pharmacy Standards